연구동향 분석

티로신 키나아제 저해제의 간독성에 대한 고찰

곽혜선 한지민 2019년

논문상세정보
인용/피인용
' 티로신 키나아제 저해제의 간독성에 대한 고찰' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • hepatotoxicity
  • mechanism
  • tyrosinekinaseinhibitors
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
87 0

0.0%

' 티로신 키나아제 저해제의 간독성에 대한 고찰' 의 참고문헌

  • Tyrosine kinases as targets for cancer therapy
    Krause DS [2005]
  • Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy
    Shah DR [2013]
  • The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity
    Park BK [1995]
  • The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment
  • The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans
  • Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity
    Ku GY [2010]
  • Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients
    Klempner SJ [2012]
  • Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism
    Kijima T [2011]
  • Role of viral infections in the induction of adverse drug reactions
    Levy M [1997]
  • Role of reactive metabolites in drug-induced hepatotoxicity
  • Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714
    Feng B [2009]
  • Role of cytochrome P450enzymes in the metabolic activation of tyrosine kinase inhibitors
    Jackson K [2018]
  • Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis
    Teo YL [2013]
  • Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity
    Moon JY [2019]
  • Reduced exposure of imatinib after coadministration with acetaminophen in mice
    Nassar I [2009]
  • Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
    Chen X [2014]
  • Prospective validation of HLA-DRB1* 07: 01 allele carriage as a predictive risk factor for lapatinib-induced liver injury
    Schaid DJ [2014]
  • Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration
    Seki N [2006]
  • Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Takeda M [2015]
  • Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes
  • Phase II trial of sorafenib in advanced thyroid cancer
  • Pharmacogenomics in drug induced liver injury
    Andrade RJ [2009]
  • P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR
    Waxman DJ [1999]
  • N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen
    Dahlin DC [1984]
  • Mechanisms of drug-induced liver disease
    Gunawan BK [2007]
  • Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
    Chen MH [2008]
  • Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes
    Murray M [1999]
  • Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib
    Teng WC [2010]
  • Mechanism of idiosyncratic drug reactions:reactive metabolites formation, protein binding and the regulation of the immune system
    Ju C [2002]
  • Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma
  • Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes
    Dai C [2015]
  • Lapatinib
    Moy B [2017]
  • Kinetics of acetaminophen glucuronidation by UDPglucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity
    Mutlib AE [2006]
  • Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDPglucuronosyltransferase isoforms
    Duan SX [2001]
  • Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors
    Liu Y [2011]
  • Impact of CYP2D6genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics
    Gan SH [2007]
  • Imatinib-induced fatal acute liver failure
    Ridruejo E [2007]
  • Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour
    Pariente A [2006]
  • Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug
    Beaune P [1987]
  • Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials
    Ghatalia P [2015]
  • Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives
    Shah RR [2013]
  • Hepatotoxicity of targeted therapy for cancer
    Lee KW [2016]
  • Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a metaanalysis of clinical trials
    Schutz FA [2011]
  • HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity:a systematic review and meta-analysis
  • HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer
    Spraggs CF [2011]
  • HLA-B* 57: 01 confers susceptibility to pazopanib-associated liver injury in patients with cancer
    Xu C-F [2016]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi T [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M [2010]
  • Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1
    Sugatani J [2013]
  • First study of the safety,tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors
    Munster PN [2007]
  • Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
    Zhou C [2011]
  • Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia
    Kim DW [2011]
  • Effects of Concomitant Medication Use on Gefitinib?Induced Hepatotoxicity
    Cho S [2018]
  • Effect of CYP3A4inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
    Teo YL [2012]
  • Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis
    Sun F [2008]
  • Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of timedependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction
    Kenny JR [2012]
  • Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
    Li J [2007]
  • Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile
    Li X [2010]
  • Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer
    Xu C [2012]
  • Characterization of dasatinib and its structural analogs as CYP3A4mechanism-based inactivators and the proposed bioactivation pathways
    Li X [2009]
  • Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients
    Powles T [2015]
  • Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States
    Chalasani N [2008]
  • Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)
    Shah RR [2013]
  • Cardiotoxicity induced by tyrosine kinase inhibitors
    Orphanos GS [2009]
  • Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities
    Li X [2009]
  • Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Xu C-F [2011]
  • Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
    Cohen MH [2002]
  • Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
    Wong WM [2000]
  • A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
    Eder JP [2010]